
SILENCE DISEASE. AMPLIFY LIFE.™ Alnylam is a leading independent biopharmaceutical company and the pioneer in RNA interference (RNAi) therapeutics – a revolutionary approach to treating diseases which “silences” the genes that cause or contribute to them. Founded in 2002 by a group of distinguished researchers and biotech leaders, Alnylam’s work over more than two decades has yielded the critical breakthroughs and advancements that have made the field of (RNAi) therapeutics possible. In 2018, our first commercial medicine, and the world’s first RNAi therapeutic was approved. Since then, five more Alnylam-developed medicines have been approved and we’re hard at work developing new therapies to treat both rare and prevalent diseases. We are a global and diverse company of 2,600+ people. We pride ourselves on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That's why we’re consistently ranked as a top employer by The Boston Globe (2015-24), Science Magazine (2018-25), Fast Company (Best Workplaces for Innovators 2020-25) and LinkedIn (2024). We are based in Cambridge, Massachusetts (U.S.), with offices throughout North America, Europe, Asia, and South America. See our social media community guidelines: https://bit.ly/2FcRhJy. Please note: If you wish to report an adverse event or product complaint, please email [email protected] or you may call us using the following telephone numbers: for North America, 877.ALNYLAM (877.256.9526), for Europe, +31 20 369 7861 Fraudulent Recruitment Activity Be aware of the potential for scams and fraudulent recruitment activity from individuals claiming to represent Alnylam Pharmaceuticals. Alnylam never conducts its interview process via messaging apps, freelance sites, or social media platforms. Alnylam team members only communicate with potential candidates through an official Alnylam email address ending in "@alnylam.com."
시장 타임라인 및 시그널 피드 잠금 해제
최근 90일간 시그널 6건.
이 회사가 각 시장에 진입한 순서 — 오래된 순부터 최신 순까지
Sr Manager, Medical Science Liaison - LOMBARDIA EST / TRIVENETO
Director, Medical Affairs
가입하고 전체 시그널 피드를 확인하세요
Alnylam Pharmaceuticals의 글로벌 확장이 경쟁사와 비교해 어떤지
막대는 비교 대상 회사 간 상대적 규모를 나타냅니다.
열5| 회사 | 시장 | 신규 시장 | 모멘텀 | 활동 | 확장 점수 |
|---|---|---|---|---|---|
Alnylam Pharmaceuticals본 회사 | 5 | 2 | 0% | 6 | 33 |
Scientist, Process Sciences
공고 보기Cambridge, MA · 지난주
Medical Science Liaison, Lead (Associate Director) - Italy
공고 보기Greater Rome Metropolitan Area · 지난주
Medical Science Liaison, Lead (Associate Director) - Italy
공고 보기Milan, Lombardy, Italy · 지난주
진행 중인 캠페인이 없습니다
이 회사를 추적하고 변화가 생기는 즉시 알림을 받으려면 가입하세요.
Alnylam Pharmaceuticals는 약물 Amvuttra의 마케팅 주장과 관련하여 FDA 조사를 받고 있으며 규제 준수 문제가 제기되고 있습니다.
나스닥은 2025년 12월 22일부터 Alnylam Pharmaceuticals와 Ferrovial SE를 포함한 6개 회사를 나스닥 100 지수에 추가한다고 발표했습니다.
나스닥100 지수가 1.58% 급등하며 반도체주가 급반등했다. 마이크론이 9.87% 상승을 주도했고, KLAC, AMAT, ASML 등 반도체 장비주도 크게 올랐다.
인증된 이메일과 직통 전화 잠금 해제
무료 · 신용카드 불필요
Alnylam Pharmaceuticals의 사업, 시장, 성장 시그널에 대한 빠른 답변입니다.

© 2026 Pubrio. 모든 권리 보유.